C

CCR Ostrava s.r.o | Ostrava, Czech Republic

Research site

(Unclaimed)

Location

28.rijna 3348/65, Ostrava, Ostrava-město, Czech Republic

Site insights

Top conditions

Top treatments

Orforglipron

LY3502970

LY3537031

Ustekinumab

Deucravacitinib

Brenipatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Active, not recruiting

Hypertension

Drug: Orforglipron

Drug: Placebo

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Active, not recruiting

Hypertension

Overweight or Obesity

Drug: Placebo

Drug: Orforglipron

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Active, not recruiting

Hypertension

Drug: Orforglipron

Drug: Placebo

New

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) (RENEW-COPD)

The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participan...

Not yet enrolling

Pulmonary Disease, Chronic Obstructive

Drug: Placebo

Drug: Brenipatide